Untitled

Tada, Tsuyoshi; Takizawa, Takeomi; Nakazato, Fumi; Kobayashi, Shigeaki; Koike, Kenichi; Oguchi, Masahiko; Ishii, Eizaburo; Amano, Yoshihiko

doi:10.1023/a:1006395719917

Cited by 39 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a small number of patients do not respond well to ICE-based regimens. Some authors have introduced high-dose chemotherapy with stem cell support in these patients and reported satisfactory results [22,24]. Therefore, more aggressive regimens may be recommended, especially in patients with poorer prognosis, as indicated by our study.…”

Section: Discussionsupporting

confidence: 59%

Outcomes of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L under radiotherapy-based treatments

Jin

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

Background In previous studies, patients with intracranial germ cell tumour (iGCT) with pure choriocarcinoma or mixed germ cell tumours with choriocarcinoma element showed similar dismal prognoses, with median overall survival (OS) of 22 months and 1-year survival rate of approximately 60%. However, these conclusions need to be updated because radiotherapy, which is the milestone for this disease, was not applied in a number of patients. Methods Clinical data of patients with iGCTs with histologically confirmed choriocarcinoma element or beta-human chorionic gonadotropin (β-HCG) > 500 IU/L were collected from the archives of our institution and retrospectively studied. Results A total of 76 patients were eligible for this study. In terms of the initial treatment, 11 patients underwent surgery, four patients received radiotherapy, and 61 patients received chemotherapy. Except for two early deaths, all patients received radiotherapy (craniospinal irradiation [CSI], n = 23; non-CSI, n = 51). The median follow-up duration for the entire series was 63 months (range, 6–188 months). The 5-year event-free survival (EFS) and OS rates were 81.5% and 84.1%, respectively. Among patients who did not have early death or progressive disease after induction chemotherapy, multivariate analysis revealed that chemotherapy cycles (> 4 vs. ≤4) (hazard ratio [HR] for EFS 0.144, p = 0.020; HR for OS 0.111, p = 0.028) and β-HCG levels (> 3000 IU/L vs. ≤3000 IU/L) (HR for EFS 4.342, p = 0.059; HR for OS 6.614, p = 0.033) were independent factors for survival. Radiation volume (non-CSI vs. CSI) was not proven to be a prognostic factor for either EFS or OS (hazard ratio [HR] for EFS 1.902, p = 0.59; HR for OS 2.425, p = 0.49). Conclusions Patients with iGCTs with choriocarcinoma element or β-HCG > 500 IU/L showed improved survival with radiotherapy-based treatments. Additional chemotherapy cycles could result in additional survival benefits. Patients with β-HCG level > 3000 IU/L had poorer prognosis.

show abstract

Section: Discussionsupporting

confidence: 59%

Outcomes of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L under radiotherapy-based treatments

Jin

Chen

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

Arja

Bouffet

Finlay

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Multimodal strategies have significantly improved the outcomes for patients with central nervous system nongerminomatous germ cell tumors. Two large cooperative group studies have recently reported much improved outcomes compared with historical series. However, a substantial proportion of patients still attain inadequate responses to initial chemotherapy prior to irradiation, with adverse impact upon survival; optimal induction chemotherapy regimens and radiotherapy strategies are as yet unidentified. Outcomes for patients with relapsed disease remain poor. There is an obvious need to incorporate molecular studies within prospective clinical trials that will likely lead to the incorporation of targeted, more effective future treatment strategies.

show abstract

Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor

Sánchez-Sierra

Perez‐Somarriba

López

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Untitled

Cited by 39 publications

References 18 publications

Outcomes of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L under radiotherapy-based treatments

Outcomes of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L under radiotherapy-based treatments

Critical review of the management of primary central nervous nongerminomatous germ cell tumors

Syngeneic hematopoietic stem cell transplantation after mobilization failure in an adolescent with intracranial germ cell tumor

Contact Info

Product

Resources

About